Unicycive Therapeutics, Inc. (UNCY) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
UNCY Revenue Growth
UNCY Revenue Analysis (2018–2024)
As of May 7, 2026, Unicycive Therapeutics, Inc. (UNCY) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, UNCY's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $951,000 in 2022.
When compared to Healthcare sector peers including ARWR (+43539.2% YoY), CYCN (+3.7% YoY), and RMTI (-23.6% YoY). Compare UNCY vs ARWR →
UNCY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| UNCYCurrent | $0 | - | - | - | |
 ARWR | $829M | +43539.2% | +56.6% | 11.9% | |
 CYCN | $2M | +3.7% | -2.0% | -239.8% | |
 RMTI | $101M | -23.6% | +10.6% | 0.6% | |
 LPCN | $2M | -82.3% | - | - | |
 NKTR | $55M | -32.8% | -18.4% | -253.7% |
UNCY Historical Revenue Data (2018–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | -100.0% | $0 | - | $-32,117,000 | - |
| 2023 | $675K | -29.0% | $675K | 100.0% | $-20,774,000 | -3077.6% |
| 2022 | $951K | - | $951K | 100.0% | $-18,052,000 | -1898.2% |
| 2021 | $0 | - | $0 | - | $-8,977,000 | - |
| 2020 | $0 | - | $0 | - | $-2,020,000 | - |
| 2019 | $0 | - | $0 | - | $-1,963,000 | - |
| 2018 | $0 | - | $0 | - | $-952,000 | - |
See UNCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UNCY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare UNCY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonUNCY — Frequently Asked Questions
Quick answers to the most common questions about buying UNCY stock.
Is UNCY's revenue growth accelerating or slowing?
UNCY TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is UNCY's long-term revenue growth rate?
Unicycive Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is UNCY's revenue distributed by segment?
UNCY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.